For the rare case of resected, node-positive (N2) early-stage SCLC, some clinicians give four courses of adjuvant chemo-immunotherapy, followed by maintenance IO. While not based on a dedicated trial in this specific surgical setting, it's an extrapolation from the positive ADRIATIC study in non-surgical limited-stage disease.

Lurbinectedin's effectiveness in second-line SCLC is highly dependent on the chemotherapy-free interval after first-line treatment. Patients with a longer interval (>90 days) show significantly better response rates and disease control, reinforcing that "platinum sensitivity" acts as a proxy for broader cytotoxic drug sensitivity.

While lurbinectedin initially improves survival outcomes as maintenance therapy, long-term data shows the survival curves eventually converge. Experts interpret this to mean the drug provides a temporary, additive chemotherapy-like effect rather than a true synergy with immunotherapy that would produce a durable response and separate the "tails of the curves."

In community settings, a majority of Small Cell Lung Cancer patients (50-60%) deteriorate too quickly to receive second-line treatment, compared to 30% in academic centers. This highlights the disease's aggressiveness and the necessity of using the most effective treatments first, as many patients will not get a second chance.

To make clinical trials more representative of real-world SCLC patients, who are often too sick to enroll, a pragmatic approach is emerging. Allowing one initial cycle of stabilizing chemotherapy before trial inclusion is a key strategy to broaden eligibility and gather more relevant data.

Since the IMFORTE trial excluded patients with brain metastases, oncologists hold differing views. Some are purists and avoid it off-protocol, while others explain the lack of evidence (which isn't negative evidence) to the patient and consider it, especially if CNS disease is controlled, creating a personalized decision-making scenario.

Early data for Tarlatamab in SCLC maintenance reveals an 82% 12-month overall survival. This is an absolute 30% improvement over the experimental arm of the recent MFORTE trial, signaling a potential paradigm shift in treatment outcomes that far surpasses current immunotherapy combinations.

In the MFORTE trial, the survival curves for the lurbinectedin-atezolizumab arm eventually converge with the atezolizumab-only arm. This indicates the combination provides an additive benefit (delaying progression) rather than true synergy, which would have created a more durable, long-term survival advantage.

Instead of presenting the entire treatment plan upfront, clinicians introduce the Amphorte regimen (lurbinectedin maintenance) after 2-3 cycles of induction chemo-IO, once a patient has shown a response. This avoids overwhelming patients on day one and allows for a more focused discussion when the decision is relevant.